title: Continuous oral cyclophosphamide and prednisolone as a valuable treatment option for peripheral T cell lymphoma.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Tucci
authors.forename: Elisa
authors.initials: E
authors.lastname: Cerqui
authors.forename: Marco
authors.initials: M
authors.lastname: Ungari
authors.forename: Samantha
authors.initials: S
authors.lastname: Ferrari
authors.forename: Liliana
authors.initials: L
authors.lastname: Baushi
authors.forename: Fabio
authors.initials: F
authors.lastname: Facchetti
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Rossi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D003520:Cyclophosphamide; D011239:Prednisolone